Senseonics Holdings, Inc., announced that they received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense Continuous
DarioHealth Corp., a digital Therapeutics company, announced today the receipt of a license from Health Canada to sell its Dario™ Blood
POPS! Diabetes Care announced the commercial launch of their POPS!® one diabetes management system following FDA clearance in November.
Dexcom, Inc. announced last week that the company has received Health Canada approval for its next-generation Dexcom G6 CGM System for people with
The U.S. Food and Drug Administration (FDA) today permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable
Ascensia Diabetes Care announced earlier this month that it has entered into a global alliance with Zhejiang POCTech, Co., Ltd, a Chinese company
POPS! Diabetes Care received U.S. Food and Drug Administration (FDA) clearance of their POPS!® one Blood Glucose Monitoring System yesterday.
Diabeloop announced this month it has received the CE marking for its “artificial pancreas system,” dubbed the DBLG1,™ for adults
Tandem Diabetes Care®, Inc., a medical device company and manufacturer of the only touchscreen insulin pumps with continuous glucose monitoring
Xeris Pharmaceuticals Inc., submitted an NDA to the U.S. Food and Drug Administration yesterday for its Glucagon Rescue Pen, the company’s lead
Get a little dLife delivered to your inbox every week.
Leave this field empty if you’re human: